Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 3,400 shares, an increase of 61.9% from the July 31st total of 2,100 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average trading volume of 57,100 shares, the short-interest ratio is currently 0.1 days.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Evoke Pharma in a research report on Saturday, August 24th. They issued a “sell” rating on the stock.
Check Out Our Latest Stock Analysis on Evoke Pharma
Evoke Pharma Price Performance
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The business had revenue of $2.55 million for the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Dell Can Continue Winning in AI and Beyond
- Investing in the High PE Growth Stocks
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.